eryptosis; phosphatidylserine; endothelium; scavenger receptor binding phosphatidylserine and oxidized low-density lipoprotein ERYPTOSIS, THE SUICIDAL erythrocyte death, is characterized by cell shrinkage and cell membrane scrambling with exposure of phosphatidylserine at the erythrocyte surface (32) . Eryptosis may result from activation of Ca 2ϩ -permeable cation channels with subsequent increase of cytosolic Ca 2ϩ concentration (5, 6, 17, 18, 25, 27, 28, 33, 48) . The increase of cytosolic Ca 2ϩ is followed by cell shrinkage due to activation of Ca 2ϩ -sensitive K ϩ channels (12, 14) and subsequent exit of KCl with osmotically obliged water (36) . It further stimulates phospholipid scrambling of the cell membrane (4, 13, 33) . Erythrocytes may be sensitized to the scrambling effect of Ca 2ϩ by ceramide (31, 34) , which is generated by a sphingomyelinase (38) . 1 Phosphatidylserine exposure on erythrocytes provides a site for the assembly of coagulant enzymes, leading to thrombin generation and clotting (15) . Furthermore, phosphatidylserineexposing erythrocytes may adhere to the vascular wall and may thus play a decisive role in the pathogenesis of thrombosis and thrombo-occlusive diseases (2, 15, 16, 19, 47, 58, 63) . However, mechanisms possibly underlying erythrocyte-endothelial cell interaction, especially in diseases with excessive eryptosis, are not well defined.
The adhesion of phosphatidylserine-exposing cells to endothelial cells could involve the transmembrane CXC chemokine ligand 16 (CXCL16). CXCL16, also termed SR-PSOX, is a chemokine, which, in membrane-bound form, acts as scavenger receptor that binds phosphatidylserine and oxidized lowdensity lipoprotein (20, 51) . CXCL16 was found to be expressed on inflammatory cells such as dendritic cells or T-lymphocytes and is particularly abundant on lipid-laden macrophages of atherosclerotic plaques (44) . Binding to CXCL16 expressed at the cell surface is followed by internalization of the bound particles (20) . Furthermore, CXCL16 is expressed on human endothelial cells, promoting adhesion and firm arrest of leukocytes under flow conditions. The present study explored whether erythrocytes undergoing eryptosis following treatment with the Ca 2ϩ ionophore ionomycin or following energy depletion adhere to human vascular endothelial cells (HUVEC) under flow conditions. Furthermore, we studied whether this adherence could be modified by coating and functional neutralization of erythrocyte phosphatidylserine with annexin-V, by treating HUVEC with an antibody directed against CXCL16, or by decreasing CXCL16 expression in HUVEC by transfection with small interfering RNA (siRNA).
glucose, 1 CaCl2; pH 7.4 at 37°C. Extracellular glucose was removed and replenished (5 mM) as indicated. The calcium ionophore ionomycin (1 M; Sigma) was applied for 30 min to the respective solutions, or annexin-V (1:200 dilution, Roche) was added to coat and thereby functionally neutralize phosphatidylserine at the surface of eryptotic erythrocytes. Where indicated, sucrose (ϩ100 mM, 200 mM, 300 mM, or 400 mM, Sigma) was added to increase the osmolarity.
FACS analysis of annexin-V binding and forward scatter. After incubation under the respective experimental conditions, 50 l cell suspension were washed in Ringer solution containing 5 mM CaCl 2 and then stained for 20 min with Annexin-V-Fluos (1:500 dilution, Roche) under protection from light (54) . In the following, the forward scatter of the cells was determined and annexin-V fluorescence intensity was measured in FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS-Calibur (BD Biosciences).
Cell culture and silencing of human umbilical vein endothelial cells. Human umbilical vein endothelial cells (HUVEC) from early passage of culture were cultured in complete endothelial cell basal medium (PAA) containing growth factors and 10% fetal bovine serum and grown to confluency. For silencing CXCL16, HUVEC were cultured on six-well plates (2.5 ϫ 10 5 cells). The cells were subsequently transfected with 10 nM validated siRNA for CXCL16 (ID no. s33807, Ambion) or with 10 nM negative control siRNA (ID no. 4390843, Ambion) using siPORT amine transfection agent (Ambion) according to the manufacturer's protocol. The cells were used 48 h after transfection.
Quantitative real-time PCR. Silencing efficiency of CXCL16 in HUVEC was verified by quantitative real-time PCR (RT-PCR). To this end, total RNA was isolated using the Trifast Reagent (Peqlab). Reverse transcription of 2 g RNA was performed using oligo(dT)12-18 primers (Invitrogen) and SuperScript III Reverse Transcriptase (Invitrogen). cDNA samples were treated with RNase H (Invitrogen). Quantitative RT-PCR was performed with the iCycler iQ RT-PCR Detection System (Bio-Rad) and iTaqs Sybr Green Supermix with ROX (Bio-Rad) according to the manufacturer's instructions. The following primers were used (5=¡3= orientation): CXCL16 forward: GACATGCTTACTCGGGGATTG; CXCL16 reverse: CAGTGATCCTACTGGGAGGGT; hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) forward: ATTGTAATGACCAGT-CAACAGGG and HPRT1 reverse: GCATTGTTTTGCCAGTGT-CAA. The specificity of the PCR products was confirmed by analysis of the melting curves and by 2% agarose gel electrophoresis. All PCRs were performed in duplicate, and mRNA fold changes were calculated by the ⌬⌬Ct method using HPRT1 as internal reference.
Dynamic erythrocyte adhesion to endothelium in vitro. Cultured HUVEC (5 ϫ 10 5 ) were attached on sterile coverslips coated with 0.2% gelatine (Sigma-Aldrich) by overnight incubation in complete endothelial cell basal medium under cell culture conditions. Erythrocytes prepared as indicated were perfused on a HUVEC monolayer in a flow chamber model (Oligene) at arterial shear rates (1, 200 Ϫs ). The interaction events were recorded with a charge-coupled device camera (Carl Zeiss) with ϫ20 magnification, followed by analysis of the number of adherent erythrocytes per high powerfield. Preincubation of HUVEC with anti-CXCL16 antibody (4 g/ml, R&D Systems) 30 min before perfusion experiments was used for neutralizing endothelial CXCL16. Statistics. Data are expressed as arithmetic means Ϯ SE. Statistical analysis was made using t-test or paired ANOVA with Tukey's test as post test, as appropriate. n denotes the number of different erythrocyte specimens studied. The batches of erythrocytes differed moderately in their susceptibility to eryptosis. Thus, the control values were not identical in all series of experiments. To avoid any bias potentially introduced by the use of different erythrocyte batches, comparison was always made within a given erythrocyte batch.
RESULTS
As shown in Fig. 1 , an increase of extracellular osmolarity was followed by cell shrinkage, reflected by a decrease of forward scatter. In this experiment the erythrocytes behaved similar to osmometers and shrank owing to water exit driven by the imposed osmotic gradient. Cell shrinkage could further be triggered by increase of cytosolic Ca 2ϩ concentration, which activates Ca 2ϩ -sensitive K ϩ channels leading to K ϩ exit, hyperpolarization, Cl Ϫ exit, and thus to cell shrinkage (32) . Under this condition, the exit of water is secondary to cellular loss of osmolarity due to KCl exit. As shown in Fig. 2A , treatment of human erythrocytes with the Ca 2ϩ ionophore ionomycin (1 M) was indeed followed within 30 min by cell shrinkage leading to significant decrease of erythrocyte forward scatter.
Moreover, increased cytosolic Ca 2ϩ activity stimulates cell membrane scrambling with phosphatidylserine exposure at the cell surface. As illustrated in Fig. 2B , ionomycin treatment was followed by a significant increase in the percentage of annexin-V binding erythrocytes, pointing to the appearance of erythrocytes exposing phosphatidylserine at their surface. As shown in Fig. 2C , treatment with ionomycin further enhanced Fig. 3 . Effect of energy depletion on erythrocyte volume, phosphatidylserine exposure, and adhesion to endothelial cells under flow conditions. A: arithmetic means Ϯ SE (n ϭ 6) of forward scatter (FSC in arbitrary units of geo means) of erythrocytes exposed for 48 h to glucose-containing (ϩ glu, gray bar) or glucose-depleted (Ϫ glu, black bar) Ringer solution. ***P Ͻ 0.01, statistically significant difference. B: arithmetic means Ϯ SE (n ϭ 6) of the percentage of annexin-V-binding erythrocytes exposed for 48 h to glucose-containing (ϩ glu, gray bar) or glucose-depleted (Ϫ glu, black bars) Ringer solution. ***P Ͻ 0.001, statistically significant difference. C: arithmetic means Ϯ SE (n ϭ 6) of erythrocytes binding to human vascular endothelial cells (HUVEC) under flow conditions following exposure of erythrocytes for 48 h to glucose-containing (ϩ glu, gray bar) or glucose-depleted (Ϫ glu, black bar) Ringer solution. ***P Ͻ 0.001, statistically significant difference. D: arithmetic means Ϯ SE (n ϭ 10) of the percentage of annexin-V binding erythrocytes exposed for 24, 48, or 72 h to glucose-containing (gray triangles) or glucose-depleted Ringer solution (black quadrangles) as well as erythrocytes exposed for 48 h to glucose-depleted Ringer followed by replenishment of glucose (5 mM) for further 24 h (black diamond). ***P Ͻ 0.001, statistically significant difference between glucose-containing and glucose-depleted Ringer solutions. ##P Ͻ 0.01, statistically significant difference between glucose-depleted Ringer for 72 h compared with glucose replenishment (5 mM) for 24 h to glucose-depleted Ringer after 48 h. E: arithmetic means Ϯ SE (n ϭ 10) of erythrocytes binding to human vascular endothelial cells (HUVEC) under flow conditions following exposure of erythrocytes for 24, 48, or 72 h to glucose-containing (gray triangles) or glucose-depleted Ringer solution (black quadrangles) as well as erythrocytes exposed for 48 h to glucose-depleted Ringer followed by replenishment of glucose (5 mM) for further 24 h (black diamond). ***P Ͻ 0.001, statistically significant difference between glucose-containing and glucose-depleted Ringer solutions. ##P Ͻ 0.01, statistically significant difference between glucose-depleted Ringer for 72 h compared with glucose replenishment (5 mM) for 24 h to glucose-depleted Ringer after 48 h. A further series of experiments explored whether the adhesion of erythrocytes could also be triggered by energy depletion, which similarly triggers cell membrane scrambling and cell shrinkage (32) . As shown in Fig. 3A , energy depletion by removal of glucose for 48 h resulted in cell shrinkage indicated by a significant decrease of forward scatter. Moreover, glucose removal was followed by a significant increase in the percentage of annexin-V binding erythrocytes, pointing to the appearance of erythrocytes exposing phosphatidylserine at their surface (Fig. 3B) . As shown in Fig. 3C , glucose depletion for 48 h significantly enhanced the percentage of erythrocytes adhering to the HUVEC monolayer under flow at arterial shear rates in vitro. Additional experiments were performed to investigate whether the enhanced phosphatidylserine exposure after glucose depletion could be reversed by replenishment of glucose. As shown in Fig. 3 , D and E, phosphatidylserine exposure at the erythrocyte surface and adherence of erythrocytes to endothelial cells under arterial flow conditions were significantly enhanced in a time-dependent manner after incubation in glucose-free Ringer solution. Replenishing glucose (5 mM) after 48 h of glucose depletion slightly attenuated the further increase of phosphatidylserine exposure and adhesion.
Further experiments were performed to determine whether enhanced vascular adhesion of Ca 2ϩ -loaded or energy-depleted erythrocytes requires phosphatidylserine exposure at the cell surface. To this end, phosphatidylserine at the erythrocyte surface was coated with annexin-V, which firmly binds to and thus masks phosphatidylserine. As illustrated in Fig. 4A , the increased dynamic adhesion of ionomycin-treated erythrocytes to endothelial cells under flow at shear rates of 1, 200 Ϫs was significantly diminished in the presence of annexin-V (1:200 dilution). Similar observations were made in energy-depleted erythrocytes. As shown in Fig. 4B , the adhesion of glucosedepleted erythrocytes was again significantly decreased following exposure to phosphatidylserine coating annexin-V followed by perfusion over a HUVEC monolayer under arterial flow conditions. Since CXCL16 has been shown to bind phosphatidylserine and to be involved in cell adhesion processes (20, 51) , additional experiments were performed to test whether the binding of Ca 2ϩ -loaded or energy-depleted erythrocytes to endothelium under flow conditions involves CXCL16. To this end, HUVEC were exposed to an antibody directed against CXCL16 (4 g/ml). As shown in Fig. 5A , the adhesion to endothelium of ionomycin-treated erythrocytes was significantly decreased following exposure of HUVEC cells to CXCL16-blocking antibody compared to treatment with an isotype control antibody of the same concentration. To further test for a role of CXCL16 in adhesion of eryptotic erythrocytes to endothelial cells, endothelial CXCL16 expression was decreased by transfection of HUVEC with CXCL16 siRNA. Successful silencing of CXCL16 resulting in a significant reduction (Ϫ44 Ϯ 6%, n ϭ 6) of CXCL16 mRNA expressed in HUVEC was confirmed by quantitative RT-PCR. As shown in Fig. 5B , CXCL16 silencing significantly decreased the adhesion of ionomycin-treated phosphatidylserine-exposing erythrocytes to endothelial cells at arterial shear rates compared with endothelium transfected with a negative control siRNA of the same concentration.
A further series of experiments explored whether the endothelial adhesion of energy-depleted erythrocytes is similarly dependent on CXCL16 expressed on the endothelial surface. To this end, the involvement of CXCL16 was again tested utilizing blocking antibody directed against surface-expressed CXCL16. As shown in Fig. 5C , the adhesion of energydepleted erythrocytes to endothelium was significantly decreased following exposure of HUVEC to anti-CXCL16 antibody compared to treatment with the control antibody. Moreover, similar to what was seen with ionomycin-treated erythrocytes, CXCL16 silencing significantly decreased the adhesion of phosphatidylserine-exposing erythrocytes after glucose depletion (Fig. 5D) .
DISCUSSION
The present study reveals that triggering of eryptosis by either the Ca 2ϩ ionophore ionomycin or by glucose depletion results in adhesion of affected erythrocytes to endothelial cells. The binding apparently involves phosphatidylserine exposed on erythrocytes and endothelial SR-PSOX/CXCL16 under flow at arterial shear rates (1, 200 Ϫs ). Ca 2ϩ entry with subsequent increase of the cytosolic Ca 2ϩ concentration triggers erythrocyte cell membrane scrambling with subsequent phosphatidylserine exposure at the cell surface (4, 13) . Cytosolic Ca 2ϩ further activates Ca 2ϩ -sensitive K ϩ channels (12, 14) , leading to exit of K ϩ , hyperpolarization of the cell membrane, exit of Cl Ϫ , and thus cellular loss of KCl together with osmotically obliged water and subsequent cell shrinkage (36) . Following a 24-h glucose depletion, the subsequent readdition of glucose slightly attenuated but did not abrogate or even reverse the increase of phosphatidylserine exposure. Thus, under the experimental conditions chosen, the triggering of suicidal erythrocyte death by energy depletion appeared to be an irreversible process. In theory, irreversibility could be due to failure of glucose readdition to replenish ATP levels or to irreversible activation of cell membrane scrambling by transient decrease of cytosolic ATP.
Our experiments reveal that the induction of suicidal erythrocyte death (eryptosis) leads to a significant increase in the number of erythrocytes firmly adherent to vascular endothelial cells under flow conditions at arterial shear rates. There is growing evidence that erythrocyte membrane proteins can promote thrombotic diseases, most notably by increased endothelial adhesion (2) . Adhesion of eryptotic cells to the endothelial cells presumably participates in the pathophysiology of several diseases associated with enhanced eryptosis (32), such as iron deficiency (30), phosphate depletion (7), hemolytic uremic syndrome (35) , sepsis (29) , sickle cell disease (37), malaria (8, 37, 52), Wilson's disease (39) , and possibly metabolic syndrome (62) . The adhesion of eryptotic erythrocytes to endothelial cells is expected to impair microcirculation since it has been shown that phosphatidylserine-exposing erythrocytes become more adhesive to endothelium in diseases associated with an increased risk for cardiovascular complications such as diabetes or chronic renal failure (11, 42, 46) .
The present observations reveal that coating of phosphatidylserine by annexin-V markedly decreased the adhesion of eryptotic erythrocytes to vascular endothelial cells. Phosphatidylserine at the erythrocyte surface apparently binds at least partially to endothelial surface-anchored chemokine CXC ligand 16 (CXCL16), a multifunctional molecule that was described as scavenger receptor binding phosphatidylserine and oxidized low-density lipoprotein and is also termed SR-PSOX (24) . CXCL16 is produced by diverse tissues and cells including dendritic cells (21) , lymphocytes (59), vascular smooth muscle cells (55) , bone marrow stromal cells (45) , tumor cells (40, 41) , and cardiac tissue (61) . Furthermore, SR-PSOX/ CXCL16 is expressed on human endothelial cells and is strongly upregulated by stimulation with proinflammatory cytokines such as TNF-␣ or IFN-␥ (1, 26), mediators associated with inflammatory diseases or ischemia (49, 53) . Thereby the stimulation of CXCL16 production by TNF-␣ depends on NF-B, p38 MAPK, and protein kinase A (22) .
On the surface of endothelial cells, CXCL16 was shown to promote the adhesion of leukocytes under flow conditions (26, 50) . CXCL16 is further expressed in lipid-laden macrophages of atherosclerotic plaques (44) and appears initially in the endothelium at sites predisposed to atherosclerotic lesion formation promoting the adhesion of monocytes to the endothelium during atherogenesis (24) . Increased erythrocyte adhesion could parallel the increased expression of CXCL16 in inflammatory tissues or atherosclerotic plaques and thus contribute to thrombotic vascular complications.
Adhesion of eryptotic erythrocytes to phagocytosing cells fosters their clearance from circulating blood and thus predisposes to the development of anemia (32) . Earlier experiments revealed that coating of eryptotic erythrocytes with annexin-V interfered with the engulfment of the eryptotic cells by macrophages (37) . According to the present observations, the clearance of erythrocytes could be fostered by interaction of CXCL16/SR-PSOX highly expressed on macrophages and phosphatidylserine exposed on erythrocyte surfaces.
In our studies we used cultured HUVEC as endothelial monolayer. HUVEC are a widely used model for cellular interactions with the vascular endothelium under flow conditions with different shear rates representing different size of arteries (3, 9, 10, 57) . They were shown to express different adhesion receptors including ␣ v integrins (e.g., ␣ v ␤ 3 or ␣ v ␤ 5 ), ␤ 1 integrins, E-and P-selectins, laminin ␣ 5 , von Willebrand factor, and the adhesion molecules ICAM-1, PECAM-1, or VCAM-1 (3, 9) .
Our results suggest that phosphatidylserine-CXCL16/SR-PSOX interactions are linked to an increased adhesiveness of eryptotic erythrocytes to vascular endothelium under flow conditions. In accordance with past reports (60), our results show that blocking phosphatidylserines or neutralizing CXCL16 by antibodies or silencing could not completely prevent binding of phosphatidylserine exposing erythrocytes to the endothelium, indicating the presence of further adhesion pathways involved in vascular erythrocyte adhesion. Recent studies show that, besides the exposure of phosphatidylserines that were shown to interact with subendothelial thrombospondin (56) or endothelial CD36 (43) , erythrocytes express additional molecules mediating erythrocyte adhesion to HUVEC under flow. Further alternative adhesion interactions are described for the erythrocyte membrane component ICAM-4 mediating adhesion to endothelial ␣ v ␤ 3 integrins (23) or the erythrocyte Lutheran blood group/basal cell adhesion molecule (Lu/BCAM) mediating adhesive processes to endothelial cell laminin ␣ 5 (57) .
In conclusion, the present observations disclose that eryptotic erythrocytes adhere to human vascular endothelial cells at arterial shear stress. They further reveal that vascular adhesion of erythrocytes requires phosphatidylserine exposure at the erythrocyte surface and CXCL16 expression on endothelial cells. Potentially via the described mechanisms, the dynamic adhesion of eryptotic erythrocytes to the vascular wall may impede microcirculation and thus contribute to the thromboocclusive pathophysiology of disorders associated with excessive eryptosis.
